Form 4: Entrada Therapeutics CFO Executes Stock Option and Sells Shares Under 10b5-1 Plan

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, executed a transaction involving the company's stock on November 11, 2024.
• Wentworth exercised options to acquire 6,000 shares of common stock at a price of $2.10 per share.
• He then sold 8,637 shares of common stock at a weighted average price of $19.9794 per share, with individual sales ranging from $19.95 to $20.04.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
• Following these transactions, Wentworth directly owns 73,849 shares of common stock and 37,157 stock options.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction under a pre-arranged plan, which is neither positive nor negative. It is a neutral event.

Risks

• The sale of shares by a high-ranking officer could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine filing for insider transactions, and the use of a 10b5-1 plan is a common practice to avoid accusations of insider trading. The transactions are not unusual for a company with stock-based compensation.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without the risk of insider trading accusations.
• The vesting schedule of the stock options, with 25% vesting initially and the remainder over 36 months, is a typical vesting structure for employee stock options.
• The sale of shares by a CFO is not uncommon, especially when part of a pre-arranged trading plan, and is similar to what is seen at other biotech companies such as Alnylam Pharmaceuticals (ALNY) and BioMarin Pharmaceutical (BMRN).

Stakeholder Impact

• The sale of shares by the CFO could have a minor negative impact on shareholder sentiment, but the pre-arranged nature of the sale should mitigate concerns.

Key Dates

Keywords

Entrada Therapeutics, Kory James Wentworth, stock options, share sale, Rule 10b5-1, insider trading, CFO, TRDA